the glocalized network in theragenomic and personalized medicine and the genetics of individual patients safety of drugs
December 29, 2023 – Alzheimer’s disease is a neurodegenerative human disease that occurs in its most common form in people over the age of 65 and is characterized by increasing dementia. It is responsible for approximately 60 percent of the …
Alzheimer’s: Are we at the beginning of a new era of treatment? Read more »
March 01, 2023 – The gene APOE codes for apolipoprotein E (Apo-E), a protein involved in the metabolism of fats in the body of mammals. A subtype is implicated in the Alzheimer’s disease and cardiovascular diseases. Recently, researchers at Stanford University …
APOE Missense Variant Linked to Increased Alzheimer’s Disease Risk in African Americans Read more »
January 08, 2023 – In precision and/or targeted medicine of today, physicians typically start out with the determination of the patients phenotypic expression of a disease (i.e., establish a clinical finding) and then go on into finding out the patients genetic …
Genomic variants traced forward to genetic disorders: A new approach? Read more »
July 26, 2019 – “Blockchains for secure digitized medicine”. This is the title of a very interesting and important article in the Journal of Personalised Medine (JPM) as of May 28, 2019. Blockchain as an emerging technology (particularly around the hype …
The phenotype broker: Blockchain and patient phenotype Read more »
May 30, 2019 – The American Food and Drug Administration (FDA) recently approved Alpelisib (Piqray) to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor …
The PI3K inhibitor Alpelisib (Piqray) for progressing breast cancer in women (and men) Read more »
May 29, 2019 – Spinal muscular atrophy (SMA) is a group of neuromuscular disorders that result in the loss of motor neurons and progressive muscle wasting. The severity of symptoms and age of onset varies by the type. Some types are apparent at …
Gene therapy: Zolgensma to treat spinal muscular atrophy Read more »
November 08, 2018 – The American Food and Drug Administration (FDA) has just authorized the first direct-to-consumer test for detecting genetic variants in genes that may govern the metabolism of drugs in individual patients. Thus, FDA permits marketing, with special controls, the …
October 31, 2018 – The American Food and Drug Administration (FDA) recently approved Cemiplimab-Rwlc (Libtayo) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for …
August 14, 2018 – The American Food and Drug Administration (FDA) just approved Patisiran (Onpattro) infusion for the treatment of peripheral nerve disease (polyneuropathy) caused by hereditary transthyretin-mediated amyloidosis (hATTR) in adult patients. This is the first FDA-approved treatment for …
Patisiran (Onpattro): First targeted RNA-based therapy approved to treat hATTR Read more »
July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene. It is …
Ivosidenib (Tibsovo) for AML-patients with IDH1-mutations Read more »